(Representational Image)

Photo: Science Business

SII Halts COVID-19 Vaccine Production Amid Low Demand

The Serum Institute of India has halted the production of the Covishield (AstraZeneca) vaccine amid a glut of vaccine supplies. The SII's stockpile of vaccines has swelled to 200 million doses. The export of Covid vaccines had been earlier restricted, but resumed in November last year. The SII had recently appealed to the government to cut the gap between the second dose and the "precautionary" dose to just six months.

Sat, 23 Apr 2022 - 10:30 AM / by Varun Das

Tags: Covid-19, Coronavirus, COVISHIELD, Covishield vaccine, vaccine

Courtesy: The Times of India

(Representational Image)

Photo: Science Business

Kerala HC Seeks Centre's Response On Plea Re Post-Covid Vaccination Death

The Kerala HC has sought the Centre's response over a plea regarding a post-Covid-19 vaccination death. The post-mortem report of the deceased confirmed that death was due to intracranial bleeding. The Medical officer suspects that it was a case of thrombosis-with-thrombocytopenia-syndrome (TTS), a  rare but well-known adverse event associated with the adenovirus vector-based Covishield vaccine. The plea argues that the victim had not been… read-more

Mon, 18 Apr 2022 - 02:50 PM / by Varun Das

Tags: Covishield vaccine, COVISHIELD, vaccine side effects, Coronavirus Vaccines, Vaccination Drive

Courtesy: Live Law

Covishield and Covaxin

Photo: The Times of India

PGI Chandigarh To Study Covid-19 Vaccine Mixing

The PGI Chandigarh has got the approval of the drug regulator of India to study the mixing of Covid-19 vaccines. The study would help conclude what happens when a person who is fully vaccinated with either Covishield or Covaxin would respond to getting the booster dose of the other vaccine. The purpose of the study is also to compare homologous vaccination to heterologous vaccination.

Sun, 17 Apr 2022 - 12:01 PM / by Varun Das

Tags: Covid-19, Coronavirus Vaccines, Covid-19 Vaccine, Covishield vaccine, Covaxin

Courtesy: The Economic Times

Booster Shots In India

Photo: The Indian Express

SII Asks Centre To Reduce Gap Between 2nd & Booster Dose, Writes Letter

Pune based Serum Institute of India (SII) on February 4, wrote to Union Health Minister Mansukh Mandaviya, to reduce booster dose gap from nine months to three. The SII Director and Government Affairs official Prakash Kumar Singh, further asked to allow Covishield precaution dose for all above 18-years-old. The letter was written on the lines of revised guidelines, allowing booster dose for people on election duties with three months gap. … read-more

Sat, 05 Feb 2022 - 09:04 AM / by Varsha Joshi

Tags: Covishield vaccine, omicron, Booster Dose, Serum Institute of India, Union Health Ministry

Courtesy: One India

COVID-19 vaccines

Photo: Hindustan Times

India-Made COVID-19 Vaccines Likely To Get Market Approval With Capped Prices

The two COVID-19 vaccines, Covishield and Covaxin will soon get the regular market approval with capped prices. According to the Drug Controller General of India, the SII and Bharat Biotech urged the DGCI to grant regular market approval for adult population with certain conditions. If approved, vaccines will be available at Rs 275 plus Rs 150 additional charges. Notably, Covaxin and Covishield are available at Rs 1,200 and 780, respectively… read-more

Wed, 26 Jan 2022 - 08:08 PM / by Varsha Joshi

Tags: Covaxin, Covishield vaccine, Bharat biotech, Serum Institute of India, DRUG CONTROLLER GENERAL OF INDIA

Courtesy: Zee News

Adar Poonwalla, SII CEO

Photo: The Guardian

SII Applies For Full Market Authorisation To Govt Of India

Adar Poonwalla, CEO of the Serum Institute of India (SII) applied for full market authorisation of its COVID-19 vaccine, Covishield, on December 31. "Supplies of Covishield vaccine in India, exceeded 1.25 billion doses. The Government of India now has enough data to allow full market authorisation," tweeted SII CEO. The application has been submitted to the Union Government and MoHFW. Besides, SII's Covishield also export vaccine doses to… read-more

Fri, 31 Dec 2021 - 06:38 PM / by Varsha Joshi

Tags: Serum Institute of India, Adar Poonawalla, Covishield vaccine, Indian Markets, Exports

Courtesy: News 18

Serum Institute of India

Photo: LiveLaw

Serum Institute Gets Nod To Enroll 7-11 Years Old For Vaccine Trial

As per reports, India's drug regulator has allowed Covishield's maker Serum Institute of India (SII) to enroll children aged between seven to 11 years for its COVID-19 vaccine trial. The Central Drugs Standard Control Organisation's (CDSCO) subject expert panel made the recommendation after "detailed deliberation". SII is already conducting a trial of its COVID-19 vaccine in the 12-17 age group and has presented safety data for an initial 100… read-more

Tue, 28 Sep 2021 - 08:58 PM / by Harsh V Singh

Tags: Serum Institute of India, Covid Vaccination, Covishield vaccine, Covaxin

Courtesy: Reuters

11-Month Delay Between Covishield Vaccine Results In Higher Antibody Levels: Study

Photo: Tribune India

44-45 Weeks Delayed COVID Shot Response Better Against Virus, Says Researchers

According to research, the COVID antibodies response is better when there is an interval of 44-45 weeks between the first and second doses of Oxford-Covishield-Vaccine. “The encouraging results support a strategy of delayed second dosing because antibody titres (concentration) were substantially higher after the second dose among individuals with almost a year between doses than among individuals who had an 8–12 week interval," says the… read-more

Sat, 04 Sep 2021 - 11:59 AM / by Vidhi Jhunjhunwala

Tags: Covishield vaccine, Covid-19, Coronavirus, Covid-Antibodies

Courtesy: The Print

Covishield Vaccine

Photo: Bing

Govt May Limit Dosage Gap Of Covishield Vaccine For 45 Yrs Or Above

The government is soon planning to reduce the interval between the two jabs of the Covishield vaccine for those who are 45 years and 45 due to the good availability of the vaccine "In two to four weeks, dosage interval of Covishield will be reduced based on final scientific evidence," said the National Technical Advisory Group on Immunisation in India (NTAGI). The current interval is 12-16 weeks.

Thu, 05 Aug 2021 - 12:16 PM / by Umang Bafna

Tags: Covishield vaccine, Dose Gap, Covid-19 Vaccination, India

Courtesy: Mint

Covaxin & Covishield

Photo: The Week

7 EU Nations Approves SII Manufactured 'Covishield' For Travel

After India's formal request & threaten with mandatory quarantine, the seven EU nations have now agreed on June 1 to include Covishield & Covaxin in the Green Pass list. Switzerland, Iceland, and other EU nations - Austria, Germany, Slovenia, Greece, Ireland, Estonia, and Spain have accepted the Indian Serum Institute-manufactured Covishield vaccine for travel. However, Covaxine is yet to be cleared by WHO.

Fri, 02 Jul 2021 - 10:15 AM / by Manashaa Ganesan

Tags: European Union, India, Covid-19, Green Pass, Covishield vaccine

Courtesy: The Times of India